The tree · Inflammation and the body's messaging
A drug that acts only on inflammation is approved to prevent heart attacks
Low-grade inflammation that never switches off is one of the twelve published kinds of ageing damage (the "hallmarks"), and for decades the question was whether damping it, with no change to cholesterol or blood pressure, would prevent the diseases of age. In 2017 a trial of 10,061 people who had already had a heart attack showed that canakinumab, an antibody against one inflammatory signal, cut further heart attacks and strokes by about a sixth and, unexpectedly, lung cancer deaths; the regulator declined to approve it for the heart because the benefit was modest and infections rose. The answer came from an old gout pill: low-dose colchicine cut heart attacks and strokes by about a third in a 2020 trial of 5,522 people, and the United States regulator approved it for that purpose on 16 June 2023, the first anti-inflammatory drug approved to prevent heart disease.
What would count
A controlled trial in people reports that a drug acting on inflammation alone, with no effect on cholesterol, blood pressure, blood sugar or weight, lowers heart attacks, strokes or deaths more than placebo, in a peer-reviewed report. For the clinic rung: a regulator approves such a drug to prevent an age-related disease. For wide use: prescribed for that purpose in several countries to a substantial share of eligible people.
Who settles it: The peer-reviewed trial report; the regulator's approval record; published uptake figures for the wide-use rung.
Where it stands
In clinical use. Reached 16 June 2023, on the record of accessdata.fda.gov. Next rung within 5 to 20 years. The year the model reads for it is 2023, the year it reached the clinic; what has happened is not drawn.
When it reaches the clinic: the project's estimate
This is the one thing on this page that is a judgment rather than a record. It is already in the clinic, so the model reads a known year; the estimate below is for the rungs still above it and feeds nothing. Set 16 October 2026, a first pass awaiting an outside review.
| Rung | No earlier than | Most likely | No later than | |
|---|---|---|---|---|
| In wide use | 2027 | 2032 | 2050 |
Why. The drug is generic and cheap, which helps uptake, and the guidelines in Europe and the United States were adding it when this was written; the likely year for wide use is 2032, the earliest assumes guideline adoption moves prescribing within a few years, and the latest allows for the 2025 negative trial keeping it a niche choice.
Changes to this record
- 17 October 2026, notes: (nothing; text added at the end of the notes) became Added 2026-10-17, from the weekly reading of that date: on 2026-07-31 the company Novo Nordisk announced that its ZEUS trial of ziltivekimab, an antibody against the inflammatory messenger interleukin-6, in over 6,300 people with hardened arteries, chronic kidney disease and raised inflammation, lowered inflammation markers but not heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99; novo-nordisk-2026). It is the largest test since the 2017 canakinumab trial of a drug acting on inflammation alone, it rests on a company announcement and not yet a peer-reviewed report, and it is a second mark against, beside the 2025 colchicine trial, for the yearly review. No stage or year was changed.. [reading 2026-10-17] Adds the ZEUS result beside the 2025 colchicine trial, as the reading proposed. Source: A/S, 31 July 2026.
The last readings
- 17 October 2026 Left for the author
Nothing in the window: no uptake figures for colchicine prescribed for the heart, no regulator's step and no guideline change dated 2026-10-10 to 2026-10-17 was found, so the wide-use rung is untouched. One older record the leaf does not mention bears on its test: on 2026-07-31 Novo Nordisk announced that its ZEUS trial of ziltivekimab, an antibody against the inflammatory messenger interleukin-6, in more than 6,300 people with atherosclerotic disease, chronic kidney disease and raised inflammation, did not lower heart attacks, strokes or cardiovascular deaths against placebo (hazard ratio 0.99, 95 per cent confidence interval 0.88 to 1.11), while lowering inflammatory markers and raising serious infections. The company said full results would be presented at a scientific meeting later in 2026; no peer-reviewed report was found, and the company's own page could not be opened from this session. Left for the author, resolved on 17 October 2026: I would add one sentence to the leaf's notes beside the 2025 CLEAR SYNERGY line: the 2026-07-31 ZEUS readout is the largest test since the 2017 canakinumab trial of a drug that acts on inflammation alone, and it found no benefit on heart events, which is a second mark against for the yearly review. It rests on a company announcement, not the peer-reviewed report the settler names, and it is dated before the window, so the stage and the estimate do not change; whether the notes should carry a press-only negative result, and whether the estimate's latest year should allow for it, is the author's ruling. To log in the publications log once its page has been read, as the reading's rule asks: Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation (Company press release, 2026-07-31; https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587).source 1, source 2, source 3, source 4
What the story so far says about it
On the record
- 31 July 2026Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Notes
The branch's own line asks for an anti-inflammatory drug with a healthy-years result; this is a heart-disease result, which is the biggest single cause of death in old age but not healthy years as such. Uptake of colchicine for the heart has been slow, which is why the leaf stays at clinical use. A 2025 trial (CLEAR SYNERGY) that found no benefit of colchicine after a heart attack is a mark against, and the yearly review should weigh it. Added 2026-10-17, from the weekly reading of that date: on 2026-07-31 the company Novo Nordisk announced that its ZEUS trial of ziltivekimab, an antibody against the inflammatory messenger interleukin-6, in over 6,300 people with hardened arteries, chronic kidney disease and raised inflammation, lowered inflammation markers but not heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99; novo-nordisk-2026). It is the largest test since the 2017 canakinumab trial of a drug acting on inflammation alone, it rests on a company announcement and not yet a peer-reviewed report, and it is a second mark against, beside the 2025 colchicine trial, for the yearly review. No stage or year was changed.
Not yet verified
These facts in the record were written from memory or from a secondary source and have not yet been checked against the paper, the regulator's record or the registry. Nothing here is presented as settled until it is cleared, by checking it and either deleting the line or correcting the record.
- No animal rung is recorded: a 2011 mouse study (Bhaskar and colleagues, Atherosclerosis, DOI 10.1016/j.atherosclerosis.2011.02.026) found less plaque with an antibody against the inflammatory signal IL-1 beta, but whether it, or an earlier report, is the right animal record for this test was not settled.